Abbott Laboratories (NYSE:ABT) insider Daniel Gesua Sive Salvadori sold 71,157 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $55.00, for a total transaction of $3,913,635.00. Following the completion of the transaction, the insider now owns 144,955 shares of the company’s stock, valued at approximately $7,972,525. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Daniel Gesua Sive Salvadori also recently made the following trade(s):
- On Monday, October 23rd, Daniel Gesua Sive Salvadori sold 96,603 shares of Abbott Laboratories stock. The stock was sold at an average price of $56.21, for a total transaction of $5,430,054.63.
- On Tuesday, September 26th, Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock. The stock was sold at an average price of $52.95, for a total transaction of $3,307,257.00.
Shares of Abbott Laboratories (ABT) opened at $55.56 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 1 year low of $37.38 and a 1 year high of $56.69. The company has a market cap of $96,707.79, a price-to-earnings ratio of 23.05, a P/E/G ratio of 2.08 and a beta of 1.06.
Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.59 EPS. research analysts expect that Abbott Laboratories will post 2.5 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were paid a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a yield of 1.91%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s payout ratio is presently 83.47%.
WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/11/19/abbott-laboratories-abt-insider-sells-3913635-00-in-stock.html.
ABT has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective for the company in a research report on Tuesday, October 31st. Royal Bank Of Canada reiterated a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Bank of America Corporation reiterated a “buy” rating and set a $60.00 target price (up previously from $56.00) on shares of Abbott Laboratories in a research report on Wednesday, October 4th. Barclays PLC reiterated an “overweight” rating and set a $57.00 target price (up previously from $52.00) on shares of Abbott Laboratories in a research report on Saturday, July 22nd. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $65.00 target price on shares of Abbott Laboratories in a research report on Thursday, October 19th. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $56.81.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Villere ST Denis J & Co. LLC boosted its stake in Abbott Laboratories by 2.3% in the 2nd quarter. Villere ST Denis J & Co. LLC now owns 268,200 shares of the healthcare product maker’s stock worth $13,037,000 after purchasing an additional 5,950 shares during the period. Private Bank & Trust Co. boosted its stake in Abbott Laboratories by 12.3% in the 2nd quarter. Private Bank & Trust Co. now owns 30,322 shares of the healthcare product maker’s stock worth $1,473,000 after purchasing an additional 3,330 shares during the period. Comerica Securities Inc. acquired a new position in Abbott Laboratories in the 1st quarter worth $2,833,000. AQR Capital Management LLC boosted its stake in Abbott Laboratories by 264.8% in the 1st quarter. AQR Capital Management LLC now owns 634,391 shares of the healthcare product maker’s stock worth $28,173,000 after purchasing an additional 460,477 shares during the period. Finally, Century Capital Management LLC acquired a new position in Abbott Laboratories in the 1st quarter worth $4,332,000. 70.64% of the stock is owned by hedge funds and other institutional investors.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.